ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Elevai Labs Inc

Elevai Labs Inc (ELAB)

0.0189
0.001
(5.59%)
Closed November 10 3:00PM
0.0187
-0.0002
(-1.06%)
After Hours: 6:59PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
0.0187
Bid
0.0187
Ask
0.019
Volume
434,160,961
0.0183 Day's Range 0.0208
0.0161 52 Week Range 4.2442
Market Cap
Previous Close
0.0179
Open
0.0205
Last Trade Time
Financial Volume
US$ 8,467,919
VWAP
0.019504
Average Volume (3m)
51,272,959
Shares Outstanding
20,192,114
Dividend Yield
-
PE Ratio
-0.09
Earnings Per Share (EPS)
-0.21
Revenue
1.71M
Net Profit
-4.3M

About Elevai Labs Inc

Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed... Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Elevai Labs Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ELAB. The last closing price for Elevai Labs was US$0.02. Over the last year, Elevai Labs shares have traded in a share price range of US$ 0.0161 to US$ 4.2442.

Elevai Labs currently has 20,192,114 shares outstanding. The market capitalization of Elevai Labs is US$361,438.84 . Elevai Labs has a price to earnings ratio (PE ratio) of -0.09.

ELAB Latest News

Elevai Labs Inc.Β Announces Update and Extension of Pending Offer to Exchange

NEWPORT BEACH, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (β€œElevai” or the β€œCompany”), a leader in medical aesthetics, announced today that it is has amended and...

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity

NEWPORT BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- EL-22 is a novel myostatin asset for the potential treatment of obesity in combination with existing GLP-1 medicinesThe Investigational...

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity

Preclinical results of EL-32 demonstrated statistically significant increases in grip strength, motor function and body composition in aged C57BL/6J mouse model.Elevai believes that EL-32 has the...

Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock

NEWPORT BEACH, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) ("Elevai" or the "Company"), a leader in medical aesthetics, today announced the commencement of an...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0199-51.55440414510.03860.03990.01613062564500.02075121CS
4-0.0801-81.07287449390.09880.1840.01611086162860.04315764CS
12-0.2933-94.00641025640.3120.390.0161512729590.07365393CS
26-0.6362-97.14460222930.65490.70.0161236735590.07447809CS
52-3.9813-99.532544.24420.0161129094030.11196362CS
156-3.9813-99.532544.24420.0161129094030.11196362CS
260-3.9813-99.532544.24420.0161129094030.11196362CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
INODInnodata Inc
US$ 42.75
(75.64%)
9.61M
SEZLSezzle Inc
US$ 428.58
(71.11%)
632.22k
SONDSonder Holdings Inc
US$ 4.36
(60.89%)
1.42M
INDIindie Semiconductor Inc
US$ 5.50
(60.35%)
36.22M
AZIAutozi Internet Technology Global Ltd
US$ 2.54
(55.83%)
13.41M
PRPHProPhase Labs Inc
US$ 0.78
(-45.45%)
2.66M
ELWSEarlyworks Co Ltd
US$ 3.69
(-45.33%)
857.59k
ALVRAlloVir Inc
US$ 0.6103
(-37.82%)
2.16M
CHSNChanson International Holding
US$ 5.66
(-37.60%)
530.53k
RVNCRevance Therapeutics Inc
US$ 3.705
(-35.90%)
13.15M
ELABElevai Labs Inc
US$ 0.0188
(5.03%)
438.79M
TIVCTivic Health Systems Inc
US$ 0.4003
(53.67%)
292.84M
TSLATesla Inc
US$ 321.22
(8.19%)
205.04M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 19.06
(16.29%)
188.36M
NVDANVIDIA Corporation
US$ 147.63
(-0.84%)
176.85M

ELAB Discussion

View Posts
Money hunt Money hunt 3 hours ago
Fast track status going to hit the wires hard, Viva South Korea
https://www.elevaibio.com/pipeline
πŸ‘οΈ0
Money hunt Money hunt 3 hours ago
Goodnight South Korea Get ready for news tomorrow morning$$$$$
πŸ‘οΈ0
Money hunt Money hunt 13 hours ago
Fins coming out next week dudes!! who will pharma partner be? Novo Nordisk’s Ozempic® (semaglutide) & Wegovy®(semaglutide) and Eli Lilly’s Zepbound (tirzepatide), and Mounjaro® (tirzepatide)
πŸ‘οΈ0
Fire_starter Fire_starter 13 hours ago
BLOW THE ROOF OFF🔥🔥🔥🔥🔥🔥
πŸ‘οΈ0
MetaMonster MetaMonster 14 hours ago
Roaring kitty soaked up the float locked and loaded
πŸ‘οΈ0
MetaMonster MetaMonster 15 hours ago
Elon Musk is watching behind the curtains, Don't underestimate these tycoons
👍 1
MetaMonster MetaMonster 15 hours ago
Manipulating SP, illegal shorting and naked shorting all these manipulative practices will come to end soon IMO as Tesla was suffered from these practices. to to close their positions before market opens on Monday.
πŸ‘οΈ0
MetaMonster MetaMonster 16 hours ago
Goldman Sachs predicts that this epidemic will create a $100 billion market for anti-obesity players
https://www.elevaibio.com/about
πŸ‘οΈ0
MetaMonster MetaMonster 16 hours ago
The Unmet Need With Blockbuster Obesity Drugs
Approved GLP-1 drugs used in weight loss, such as Novo Nordisk’s Ozempic® (semaglutide) & Wegovy®(semaglutide) and Eli Lilly’s Zepbound (tirzepatide), and Mounjaro® (tirzepatide) have transformed the obesity treatment landscape. However, past studies of these highly effective drugs show that up to 40% of the weight loss is due to loss of lean muscle.

Physicians have expressed concern around this problematic finding as muscle is necessary for metabolism, strength, and physical function. As a result, one of the key unmet needs in the current obesity landscape is the avoidance of muscle loss while on weight loss treatments.

Elevai is developing EL-22, an engineered probiotic with myostatin antigens, to elicit an immune response that could help people achieve substantial fat loss while preserving muscle mass.
πŸ‘οΈ0
MetaMonster MetaMonster 16 hours ago
Targeting obesity with next-generation treatments
Elevai Biosciences is advancing a first-in-class approach to address obesity’s pressing issue of preserving muscle while on GLP-1 treatments.

A New Treatment Paradigm: Next-Generation Obesity Treatment
Our clinical-stage lead candidate, EL-22, activates the body’s own immune system to inhibit myostatin, a negative regulator of muscle growth.

Data suggests that blocking myostatin causes muscle cell growth and increases muscle power. Combining this muscle targeting approach with existing GLP-1 therapies for weight-loss could have significant promise and a lasting impact in helping obese patients lose fat, while preserving lean muscle mass.
πŸ‘οΈ0
MetaMonster MetaMonster 16 hours ago
Is it Monday yet!? Never thought I’d be excited for the weekend to be over
πŸ‘οΈ0
MetaMonster MetaMonster 16 hours ago
Hope it's a huge multinational pharmaceutical monster so they can blow the shorts one way to hell where they belong forever, rot in hell short bastards
πŸ‘οΈ0
Money hunt Money hunt 19 hours ago
https://www.investing.com/news/company-news/elevai-biosciences-gears-up-for-obesity-drug-ind-submission-93CH-3675333#
πŸ‘οΈ0
Money hunt Money hunt 20 hours ago
Partnership News is coming https://www.globenewswire.com/news-release/2024/10/03/2957611/0/en/Elevai-Biosciences-a-Subsidiary-of-Elevai-Labs-Inc-Expands-Patent-Portfolio-with-Two-New-Filings-for-EL-22-in-Muscle-Loss-Treatment-for-Obese-Patients-Including-GLP-1-Receptor-Agon.html
👍 1
Money hunt Money hunt 20 hours ago
Billion dollar market cap overnight In a phase I study conducted in Seoul, South Korea, in 37 healthy adult volunteers, EL-22 demonstrated good safety and a tolerable profile.

A New Method of Myostatin Inhibition in Mice via Oral Administration of Lactobacillus casei Expressing Modified Myostatin Protein
AUG 2022
πŸ‘οΈ0
MetaMonster MetaMonster 20 hours ago
Short squeeze the living shit out of these dirty rat bastards till they croak and burn in hell
πŸ‘οΈ0
Ms Labonte Ms Labonte 20 hours ago
$how me the money $weet$$$ $wiss boy$$ on the loose$$$
πŸ‘οΈ0
Ms Labonte Ms Labonte 20 hours ago
Leg$$ up on monday$$$$$$$ $liver Monday open!!!
πŸ‘οΈ0
Fire_starter Fire_starter 21 hours ago
HAIL BREAKTHROUGH FAST TRACK STATUS🔥🔥🔥🔥🔥🔥
πŸ‘οΈ0
Fire_starter Fire_starter 21 hours ago
BLAST OFF 🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥
πŸ‘οΈ0
Bigtrade PT Bigtrade PT 21 hours ago
🚀🚀🚀
πŸ‘οΈ0
Ms Labonte Ms Labonte 21 hours ago
I Hope y’all realize there is 0 $hare$ to $hort $weet$$)
πŸ‘οΈ0
Money hunt Money hunt 21 hours ago
Shares after hour went dry… ah we about to strap in for a ride dude!! Surfs up
πŸ‘οΈ0
Fire_starter Fire_starter 21 hours ago
FIRE AT WILL🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥
πŸ‘οΈ0
Fire_starter Fire_starter 21 hours ago
🔥🔥🔥SOUND ALL ALARMS 🔥🔥🔥🔥
πŸ‘οΈ0
MetaMonster MetaMonster 21 hours ago
These dirty rat bastard shorts took us longs to the cleaners, broke and homeless, time to turn the tables and squeeze the living shit out of these bastard rats of the earth,
πŸ‘οΈ0
MetaMonster MetaMonster 21 hours ago
Need big fucken news so the shorts can croak in hell in rats vomit
πŸ‘οΈ0
MetaMonster MetaMonster 21 hours ago
Lets send these dirty rotten scumbag bastard shorts in hell where they belong broke and homeless
πŸ‘οΈ0
Fire_starter Fire_starter 21 hours ago
TAKE OUT THE NEWS AND SHOCK THE WORLD
πŸ‘οΈ0
Fire_starter Fire_starter 21 hours ago
WHALES BOTTOM FEEDING FRENZY🔥🔥🔥🔥
πŸ‘οΈ0
Fire_starter Fire_starter 21 hours ago
🔥🔥🔥MOASS KRAKEN NEWS🔥🔥🔥🔥
πŸ‘οΈ0
Money hunt Money hunt 22 hours ago
Just caught a whale with a 17m Share bite in PM yesterday buy banging in the bank
πŸ‘οΈ0
Ms Labonte Ms Labonte 22 hours ago
$hort$ in full scale trouble with swi$$ pimp$$$ on the line
πŸ‘οΈ0
Ms Labonte Ms Labonte 22 hours ago
Fliptards are out of ammo $weet$$You can all drop your pant$ and $lap my a$$ I got you
πŸ‘οΈ0
Ms Labonte Ms Labonte 22 hours ago
Drop your pant$ $weet$$ $hort$ out of ammo$$
πŸ‘οΈ0
Money hunt Money hunt 24 hours ago
Viva South Korea https://www.wsj.com/market-data/quotes/KR/XKRX/142760/company-people#:~:text=MOA%20Life%20Plus%20Co.%2C%20Ltd,plantarum%20BLS41%2C%20and%20skincare%20products.
https://tvfan.fandom.com/wiki/VIVA_(South_Korea)
πŸ‘οΈ0
Money hunt Money hunt 1 day ago
We hit the jackpot dudes!! Fast track blue skies status
πŸ‘οΈ0
Money hunt Money hunt 1 day ago
NIH Material dude!!
New Method of Myostatin Inhibition in Mice via Oral Administration of Lactobacillus casei Expressing Modified Myostatin Protein, BLS-M22
https://pmc.ncbi.nlm.nih.gov/articles/PMC9409196/
πŸ‘οΈ0
Money hunt Money hunt 1 day ago
We can count our lucky stars In a phase I study conducted in Seoul, South Korea, in 37 healthy adult volunteers, EL-22 demonstrated good safety and a tolerable profile.

A New Method of Myostatin Inhibition in Mice via Oral Administration of Lactobacillus casei Expressing Modified Myostatin Protein

August 2022
https://www.elevaibio.com/pipeline
πŸ‘οΈ0
Money hunt Money hunt 1 day ago
A New Treatment Paradigm: Next-Generation Obesity Treatment
Our clinical-stage lead candidate, EL-22, activates the body’s own immune system to inhibit myostatin, a negative regulator of muscle growth.

Data suggests that blocking myostatin causes muscle cell growth and increases muscle power. Combining this muscle targeting approach with existing GLP-1 therapies for weight-loss could have significant promise and a lasting impact in helping obese patients lose fat, while preserving lean muscle mass.

https://www.elevaibio.com/
πŸ‘οΈ0
Money hunt Money hunt 1 day ago
That’s massive support lmao dude!! Never know in these crazy times.
πŸ‘οΈ0
Money hunt Money hunt 1 day ago
Partnership agreement with big pharma news can send this viral
πŸ‘οΈ0
MetaMonster MetaMonster 1 day ago
Word is out on the streets Elon Musk is behind the curtains
πŸ‘οΈ0
MetaMonster MetaMonster 1 day ago
They need to get squeezed till they spit blood, Dirty rat short scumbag bastards fried all shareholders to dirt on the Streets,
πŸ‘οΈ0
MetaMonster MetaMonster 1 day ago
Volume here opened Saudi kingdom's eyes, Watching carefully for the ultimate trigger next week
πŸ‘οΈ0
MetaMonster MetaMonster 1 day ago
Maximum authorized shares 300 Million
πŸ‘οΈ0
MetaMonster MetaMonster 1 day ago
Are we the lucky ones or the bagholders? Lets flip the coin
πŸ‘οΈ0
MetaMonster MetaMonster 1 day ago
Is EL-22 another Nobel micro RNA target for blockbuster obesity drug like RNAZ Nobel TTX platform technology
πŸ‘οΈ0
Money hunt Money hunt 1 day ago
Hello South Korea !! How you doing dudes!!
πŸ‘οΈ0
Money hunt Money hunt 1 day ago
Return big time with a monster super short squeeze breakthrough news
https://financialpost.com/globe-newswire/elevai-labs-acquires-exclusive-license-to-two-myostatin-muscle-loss-prevention-assets-with-plan-to-develop-in-combination-with-glp-1-obesity-treatments
👍 1

Your Recent History

Delayed Upgrade Clock